MTOR and metastatic neoplasm: At the time of referral to the CCTT the patient had metastatic disease to her lungs, mediastinum, peritoneum and liver and subsequently received the experimental therapy with mTOR inhibitor everolimus (7.5 mg orally every other day) and multikinase inhibitor pazopanib (600 mg orally every other day), which was matched to a molecular abnormality activating the PI3K/AKT/mTOR pathway (NF1 R1241*mutation).